Ved­aBio launch­es with $40M+ in ini­tial fund­ing for CRISPR-based mol­e­c­u­lar de­tec­tion tech­nol­o­gy

Last year
Financing
Startups

Gilead makes a $100M bet that As­sem­bly Bio can ad­vance an­tivi­rals, toss­ing life­line to strug­gling biotech

Last year
Deals

Spark lines up next reti­nal gene ther­a­py pact in Barcelona

Last year
Deals
Pharma

Bris­tol My­ers scores an­oth­er Op­di­vo ap­proval, as Mer­ck con­verts AA to full ap­proval for Keytru­da in MCC

Last year
Pharma
FDA+

PhRMA, top De­moc­rats urge Supreme Court to take up abor­tion pill case

Last year
FDA+
Law

Lon­za un­veils two sep­a­rate vac­cine, ADC man­u­fac­tur­ing deals that could lead to 415 new Swiss jobs

Last year
Deals
Manufacturing

Ab­b­Vie’s Skyrizi helps more Crohn's pa­tients stay off steroids than J&J’s Ste­lara, PhI­II da­ta show

Last year
R&D
Pharma

Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Last year
Financing
R&D

Aldeyra braces for po­ten­tial dry eye dis­ease re­jec­tion af­ter FDA says more da­ta are nec­es­sary

Last year
FDA+

Nu­va­lent’s $300M of­fer­ing; Spark ends epilep­sy deal; A small IPO

Last year
News Briefing

Omeros drug fails a PhI­II kid­ney tri­al, stock near­ly halved

Last year
R&D

No­vo Nordisk to buy PhI­II kid­ney dis­ease drug from Sin­ga­pore's KBP Bio­sciences

Last year
Deals
Pharma

Tang Cap­i­tal con­tin­ues biotech buy­ing spree with ac­qui­si­tion bid for Rain On­col­o­gy

Last year
Deals

Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Last year
People
Financing

Synaf­fix joins forces with So­tio on $740M ADC li­cens­ing deal, plans ex­pan­sion af­ter Lon­za ac­qui­si­tion

Last year
Manufacturing

BioN­Tech ex­pects up to $950M in Covid vac­cine write-offs af­ter Pfiz­er low­ers ex­pec­ta­tions

Last year
Financing
Coronavirus

BMS buys Mi­rati for $4.8B; Pfiz­er to slash cost; Q&A with Ver­tex CSO; Al­ny­lam's On­pat­tro set­back; and more

Last year
Weekly

Up­dat­ed: Pfiz­er plans $3.5B in cost cuts amid Covid slide, while Mod­er­na sticks by guid­ance

Last year
Pharma

Pfiz­er's El­rex­fio, Astel­las' Veozah among new drugs rec­om­mend­ed for au­tho­riza­tion by Eu­ro­pean reg­u­la­to­ry com­mit­tee

Last year
Pharma
FDA+

HHS se­lects in­tranasal vac­cine can­di­dates for Project NextGen, doles out $500M in funds

Last year
Financing

Ex­clu­sive: Hori­zon CEO Tim Wal­bert talks M&A, FTC post-Am­gen deal close

Last year
People
Pharma

Re­lay Ther­a­peu­tics points to drug price ne­go­ti­a­tions for de­lay in po­ten­tial block­buster can­cer drug

Last year
Pharma
Law

No­vo rais­es 2023 out­look due to high­er than ex­pect­ed Ozem­pic and We­govy sales in the US

Last year
Pharma

So­tio ter­mi­nates three tri­als study­ing its IL-15 su­per­ag­o­nist due to ‘in­suf­fi­cient ef­fi­ca­cy’

Last year
R&D
First page Previous page 263264265266267268269 Next page Last page
A service from the Financial Times